Contact
searchSearch
HMP Global
Quiz

QUIZ: Gout Attacks and Canakinumab

10/24/2018

The use of canakinumab can lower the incidence of gout attacks without changing serum uric acid levels. What is the ideal frequency of canakinumab administration?

Incorrect

The correct answer is "Every 3 months." According to researchers, “quarterly canakinumab administration was associated with significantly reduced risk for gout attacks without any change in serum uric acid levels."


Read more about the study here.

Correct!

According to researchers, “quarterly canakinumab administration was associated with significantly reduced risk for gout attacks without any change in serum uric acid levels."


Read more about the study here.

Popular Articles

Dr Ching-Lung Cheung
Q&A
Ching-Lung Cheung, PhD, on the Health Burden of Osteoporotic Fractures Among the Aging Population
09/29/2023
Dr Cheung agreed to answer a few question about his recent study highlighting an urgent need for better strategies in hip fracture prevention and care.
Dr Cheung agreed to answer a few question about his recent study highlighting an urgent need for better strategies in hip fracture prevention and care.
Dr Cheung agreed to answer a few...
09/29/2023
Rheumatology & Arthritis
Fleischmann
Podcast
Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA
11/07/2023
Dr Fleishmann reviews a post hoc analysis he and colleagues conducted of the SELECT phase 3 trial of upadacitinib in rheumatoid arthritis and the safety of JAK inhibitors among RA patients at risk for cardiovascular events.
Dr Fleishmann reviews a post hoc analysis he and colleagues conducted of the SELECT phase 3 trial of upadacitinib in rheumatoid arthritis and the safety of JAK inhibitors among RA patients at risk for cardiovascular events.
Dr Fleishmann reviews a post hoc...
11/07/2023
Rheumatology & Arthritis
SPONSORED
SKYRIZI (risankizumab-rzaa) Safety and Efficacy
03/19/2024
Understand the safety and efficacy of SKYRIZI for the treatment of adults with active psoriatic arthritis (PsA).
Understand the safety and efficacy of SKYRIZI for the treatment of adults with active psoriatic arthritis (PsA).
Understand the safety and...
03/19/2024
Rheumatology & Arthritis
Sponsored Video
Cytokines and the Future of Rheumatology
04/30/2024
In part 1 of this video series, Professor Iain McInnes of the University of Glasgow discusses how advances in molecular medicine have revolutionized the treatment of axial spondyloarthritis.
In part 1 of this video series, Professor Iain McInnes of the University of Glasgow discusses how advances in molecular medicine have revolutionized the treatment of axial spondyloarthritis.
In part 1 of this video series,...
04/30/2024
Rheumatology & Arthritis
News
Meta-Analysis Finds Robust Evidence Supporting Upadacitinib for axSpA
09/18/2024
Jolynn Tumolo
Upadacitinib was associated with significant improvements in several key outcomes, including low disease activity.
Upadacitinib was associated with significant improvements in several key outcomes, including low disease activity.
Upadacitinib was associated with...
09/18/2024
Rheumatology & Arthritis

Stay in the Know

Rheumatology & Arthritis Newsletter

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1
SPONSORED
Axial Involvement in SpA, Chapter 1
04/26/2022
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses...
04/26/2022
Rheumatology & Arthritis

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use